About Glaukos corporation
Glaukos Corporation: Transforming Lives with Innovative Therapies
Glaukos Corporation is a leading medical technology company that specializes in developing and delivering innovative therapies for patients suffering from glaucoma, corneal disorders, and retinal diseases. The company was founded in 1998 by Olav Bergheim, M.D., Ph.D., and Richard Hill, who shared a vision of transforming the treatment of glaucoma through the development of novel micro-scale devices.
Since its inception, Glaukos has been at the forefront of innovation in ophthalmology. The company's flagship product is the iStent®, a tiny implant that is inserted into the eye to improve fluid outflow and reduce intraocular pressure (IOP) in patients with mild to moderate open-angle glaucoma. The iStent® has been shown to be safe and effective in numerous clinical studies, and it has received regulatory approval in more than 100 countries worldwide.
In addition to the iStent®, Glaukos offers a range of other products designed to address unmet needs in ophthalmology. These include:
- The iStent inject® Trabecular Micro-Bypass System: A next-generation version of the original iStent® that allows for greater flexibility during implantation.
- The iDose™ Travoprost: A sustained-release drug delivery system that delivers medication directly into the eye over an extended period.
- The KDB™ Glide: A single-use diamond blade designed for use during minimally invasive glaucoma surgery (MIGS).
- The Canaloplasty System: A comprehensive surgical approach for lowering IOP by restoring natural outflow pathways within the eye.
Glaukos' commitment to innovation extends beyond its product portfolio. In recent years, the company has invested heavily in research and development (R&D), with a particular focus on exploring new approaches to treating corneal disorders and retinal diseases. This includes ongoing clinical trials investigating novel drug delivery systems as well as gene therapy approaches.
At Glaukos, patient care is at the heart of everything we do. We understand how debilitating these conditions can be for those affected by them – not just physically but emotionally as well – which is why we are dedicated to developing therapies that can make a real difference in people's lives.
Our team consists of some of the brightest minds in ophthalmology – from engineers and scientists to clinicians and business professionals – all working together towards our shared goal of improving patient outcomes through innovation.
We are proud to have received numerous awards over our two-decade history recognizing our contributions both within our industry as well as within our local communities. These include being named one of Forbes' Most Innovative Growth Companies three years running (2016-2018) as well as receiving recognition from organizations such as Ophthalmology Times, Deloitte Technology Fast 500™, Red Herring Top 100 North America Award Winner, Fierce Innovation Awards - Life Sciences Edition among others
In conclusion,
Glaukos Corporation continues its relentless pursuit towards creating transformative therapies for patients struggling with various ocular conditions like glaucoma or corneal disorders or retinal diseases since its inception back on 1998 by Olav Bergheim & Richard Hill who had envisioned revolutionizing treatment methods using micro-scale devices; today they have achieved this vision through their flagship product "iStent" which has gained regulatory approval across more than hundred countries worldwide along with other products like "iDose", "KDB Glide", "Canaloplasty System" etc., all aimed at addressing unmet needs while also investing heavily into R&D exploring new approaches towards treating ocular conditions including gene therapy approaches; all this while keeping patient care at heart making them one among Forbes' Most Innovative Growth Companies three years running(2016-2018).